Antiphospholipid Syndrome: General Features

  • T. Godfrey
  • D. D’Cruz


The first papers on the antiphospholipid syndrome (APS) described recurrent arterial and venous thromboses and fetal losses. These remain the characteristic clinical features of this syndrome although the spectrum of associated symptoms and signs has broadened considerably over the last 15 years. The aim of this chapter is to give a clinical overview and preliminary classification criteria for the APS by way of introduction to the more detailed chapters that follow.


Systemic Lupus Erythematosus Systemic Lupus Erythematosus Patient Acquire Immune Deficiency Syndrome Lupus Anticoagulant Anticardiolipin Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Piette JC, Cacoub P. Antiphospholipid syndrome in the elderly: caution. Circulation 1998; 97: 2195–2196.PubMedCrossRefGoogle Scholar
  2. 2.
    Perez-Vazquez ME, Villa A, Drenkard C, Cabiedes J, Alarcon-Segovia D: Influence of disease duration, continued follow up and further antiphopholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with SLE. J Rheumatol 1993; 20: 437–42.PubMedGoogle Scholar
  3. 3.
    Molina JF, Gutierrez-Urena S, Molina J et al. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol 1997; 1997; 24: 291–296.Google Scholar
  4. 4.
    Sebastiani GD, Galeazzi M, Morozzi G, Marcolongo R: The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies,and lupus anticoagulant. Semin Arthritis Rheum 1996; 25: 414–420.PubMedCrossRefGoogle Scholar
  5. 5.
    Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Report of an International Workshop. Arthritis Rheum 1999; 42: 1309–1311.PubMedCrossRefGoogle Scholar
  6. 6.
    Piette JC: Criteria for the antiphospholpid syndrome. Lupus 1998; 7 (Suppl 2): S149 - S157.PubMedCrossRefGoogle Scholar
  7. 7.
    Cervera R, Font J, Lopez-Soto A et al. Isotype distribution of anticardiolipin antibodies in SLE, prospective analysis of 100 patients. Ann Rheum Dis 1990; 49: 109–113.PubMedCrossRefGoogle Scholar
  8. 8.
    Alarcon-Segovia D, Deleze M, Oria CV et al. Antiphospholipid antibodies and the antiphospholipid syndrome in SLE. A prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353–365.PubMedGoogle Scholar
  9. 9.
    Merkel P, Chang Y, Pierangeli S, Convery K, Harris N, Polisson R. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med; 1996; 101: 576–583.PubMedCrossRefGoogle Scholar
  10. 10.
    Petri M. Update on antiphospholipid antibodies. Curr Opin Rheumatol 1998; 10: 426–430.PubMedCrossRefGoogle Scholar
  11. 11.
    Perez-Vazquez ME, Cabiedes J, Cabral AR, Alarcon-Segovia D. Decrease in serum antiphospholipid antibodies upon development of the nephrotic syndrome in patients with SLE: relationship to urinary losses of IgG and other factors. Am J Med 1992; 92: 357–363.PubMedCrossRefGoogle Scholar
  12. 12.
    Silveira LH, Jara LJ, Espinoza LR. Transient disappearance of serum antiphospholipid antibodies can also be due to prednisolone therapy. Clin Exp Rheumatol 1996; 14: 217–226.PubMedGoogle Scholar
  13. 13.
    Drenkard C, Sanchez-Guerrero J, Alarcon-Segovia D. Fall in antiphospholipid antibody at time of thromboocclusive episodes in SLE. J Rheumatol 1989; 16: 614–617.PubMedGoogle Scholar
  14. 14.
    Faghiri Z, Taheri F, Wilson WA et al. IgA is the most prevalent isotype of anticardiolipin and anti-ß2 glycoprotein-1 antibodies in Jamaican and African-American SLE patients. Lupus 1998; 7 (Suppl 2): S185.Google Scholar
  15. 15.
    Selva-O’Callaghan A, Ordi-Ros J, Monegal-Ferran F, Martinez N, Cortes-Hernandez F, VilardellTarres M. IgA anticardiolipin antibodies–relation with other antiphospholipid antibodies and clinical significance. Thromb Haemost 1998; 79: 282–285.PubMedGoogle Scholar
  16. 16.
    Bertolaccini ML, Atsumi T, Amengual O, Katsumata K, Khamashta MA, Hughes GRV. IgA anticardiolipin antibody testing does not contribute to the diagnosis of antiphospholipid syndrome in patients with SLE. Lupus 1998; 7 (Suppl 2): S184.Google Scholar
  17. 17.
    Lopez LR, Santos ME, Espinoza LR, La Rosa FG. Clinical significance of IgA versus IgG and M anticardiolipin antibodies in patients with SLE. Am J Clin Pathol 1992; 98: 449–454.PubMedGoogle Scholar
  18. 18.
    McCarty GA, Freeland E,Wagenknecht DR, McIntyre JA. Antiphospholipid antibody syndrome in 28 patients with IgA as the sole antibody isotype. Lupus 1998; 7 (Suppl 2): S186.Google Scholar
  19. 19.
    Wilson WA, Morgan OC, Barton EN et al. IgA antiphospholipid antibodies in HTLV1 associated tropical spastic paraparesis. Lupus 1995; 4: 138–141.PubMedCrossRefGoogle Scholar
  20. 20.
    Tsutsumi A, Matsuura E, Ichikawa K et al. Ig A class anti ß2 glycoprotein 1 in patients with SLE. J Rheumatol 1998; 25: 74–78.PubMedGoogle Scholar
  21. 21.
    Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GR. Specificity of ELISA for antibody to beta 2 glycoprotein 1 in patients with antiphospholpid syndrome. Br J Rheumatol 1996; 35: 1239–1243.PubMedCrossRefGoogle Scholar
  22. 22.
    Nencini P, Baruffi M, Abbate R, Massai G, Amaducci L, Inzitari D. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischaemia. Stroke 1992; 23: 189–193.PubMedCrossRefGoogle Scholar
  23. 23.
    Fields R, Toubbeh H, Searles R, Bankhurst A. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989; 16: 623–625.PubMedGoogle Scholar
  24. 24.
    Antiphospholipid Antibodies in Stroke Study Group. Clinical, radiological, and pathological aspects of cerebrovascular disease associated with antiphospholipid antibodies. Stroke 1993; 24 (Suppl 1): S1–123.Google Scholar
  25. 25.
    Schved JF, Dupuy-Fons C, Biron C, Quere I, Janbon C. A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) Study. Haemostasis 1994; 24: 175–182.PubMedGoogle Scholar
  26. 26.
    Ginsberg J, Wells P, Brill-Edwards P et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685–3691.PubMedGoogle Scholar
  27. 27.
    Kearon C, Gent M, Hirsh J, Weitz J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901–907.PubMedCrossRefGoogle Scholar
  28. 28.
    Schulman S, Svenungsson E, Granqvist S and the Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104: 332–338.PubMedCrossRefGoogle Scholar
  29. 29.
    Simioni P, Prandoni P, Zanon E et al. Deep venous thrombosis and lupus anticoagulant. A case-control study. Thromb Haemost 1996; 76: 187–189.PubMedGoogle Scholar
  30. 30.
    Ghirardello A, Doria A, Ruffatti A et al. Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome. Ann Rheum Dis 1994; 53: 140–142.PubMedCrossRefGoogle Scholar
  31. 31.
    Horbach DA, van Oort E, Donders RC et al. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus–comparison between different assays for the detection of antiphospholpid antibodies, Thromb Haemost 1996; 76: 916–924.PubMedGoogle Scholar
  32. 32.
    Vaarala O, Puurunen M, Manttari M et al. Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23–27.PubMedCrossRefGoogle Scholar
  33. 33.
    Bongard O, Reber G, Bounameaux H, deMoerloose P. Anticardiolipin in acute venous thromboembolism. Thromb Haemost 1992; 67: 724.PubMedGoogle Scholar
  34. 34.
    Wahl DG, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998; 7: 15–22.PubMedCrossRefGoogle Scholar
  35. 35.
    Ginsburg K, Liang M, Newcomer L et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997–1002.PubMedGoogle Scholar
  36. 36.
    Schmidt R, Auer-Grumbach P, Fazekas F, Offenbacher H, Kapeller P. Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings. Stroke 1995; 26: 749–754.PubMedCrossRefGoogle Scholar
  37. 37.
    Chakravaty KK, Byron MA, Webley M et al. Antibodies to cardiolipin in stroke: Association with mortality and functional recovery in patients without systemic lupus erythematosus. Q J Med 1991; 79: 397–405.Google Scholar
  38. 38.
    Kittner S, Gorelick P. Antiphospholipid antibodies and stroke: an epidemiological perspective. Stoke 1992;23 (Suppl 1): 1–19, 1–22.Google Scholar
  39. 39.
    Abu-Shakra M, Gladman DD, Urowitz MB, Farewell V. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med 1995; 99: 624–628.PubMedCrossRefGoogle Scholar
  40. 40.
    Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus. A meta-analysis. Lupus 1997; 6: 467–473.PubMedCrossRefGoogle Scholar
  41. 41.
    Shah NM, Khamashta MA, Atsumi T, Hughes GRV. Outcome of patients with anticardiolipin antibodies: a 10 year follow up of 52 patients. Lupus 1998; 7: 3–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Jouhikainen T, Stephansson E, Leirisalo-Repo M. Lupus anticoagulant as a prognostic marker in systemic lupus erythematosus. Br J Rheumatol 1993; 32: 568–573.PubMedCrossRefGoogle Scholar
  43. 43.
    Finazzi G, Brancaccio V, Moia M et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies. A four year prospective study from the Italian Registry. Am J Med. 1996; 100: 530–536.PubMedCrossRefGoogle Scholar
  44. 44.
    Khamashta M, Cuadrado M, Mujic F, Taub N, Hunt B, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993–997.PubMedCrossRefGoogle Scholar
  45. 45.
    Emlen W. Antiphospholipid antibodies: new complexities and new assays. Arthritis Rheum 1996; 39: 1441–1443.PubMedCrossRefGoogle Scholar
  46. 46.
    Rosendaal F. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 1997; 78: 1–6.PubMedGoogle Scholar
  47. 47.
    Brenner B, Vulfsons SL, Lanir N, Nahir M. Coexistence of familial antiphospholipid syndrome and factor V Leiden: impact on thrombotic diathesis. Br J Haematol 1996; 94: 166–167.PubMedCrossRefGoogle Scholar
  48. 48.
    Alarcon-Segovia D, Ruiz-Arguelles GJ, Garces-Eisele J, Ruiz-Arguelles. Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome. J Rheumatol 1996; 23: 2162–2165.PubMedGoogle Scholar
  49. 49.
    Ames P, Tommasino C, D’Andrea G, Iannaccone L, Brancaccio V, Margaglione M. Thrombophilic genotypes in subjects with idiopathic antiphospholpid antibodies–prevalence and significance. Thromb Haemost 1998; 79: 46–49.PubMedGoogle Scholar
  50. 50.
    Schutt M, Kluter H, Hagedorn-Greiwe M, Fehm HL, Wiedemann GJ. Familial coexistence of primary antiphospholipid syndrome and factor V Leiden. Lupus 1998; 7: 176–82.PubMedCrossRefGoogle Scholar
  51. 51.
    Peddi VR, Kant KS. Catastrophic secondary antiphospholipid syndrome with concomitant antithrombin III deficiency. J Am Soc Nephrol 1995; 5: 1882–1887.PubMedGoogle Scholar
  52. 52.
    Asherson RA, Khamashta MA, Ordi-Ros J et al. The primary antiphospholipid syndrome: major clinical and serological features. Medicine 1989; 68: 366–374.PubMedCrossRefGoogle Scholar
  53. 53.
    Soweid AM, Hajjar RR, Hewan-Lowe KO, Gonzalez EB. Skin necrosis indicating antiphospholipid syndrome in patient with AIDS. S Med J 1995; 88: 786–778.CrossRefGoogle Scholar
  54. 54.
    Labarca J, Rabaggliati R, Radrigan F et al Antiphospholipid syndrome associated with cytomegalovirus infection: case report and review. Clin Infect Dis 1997; 24: 197–200.PubMedCrossRefGoogle Scholar
  55. 55.
    Merrill JT, Shen C, Gugnani M, Lahita RG, Mongey AB. High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol 1997; 24: 1083–1088.PubMedGoogle Scholar
  56. 56.
    Vianna JL, Khamashta MA, Ordi-Ros J et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 1994; 96: 3–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Piette JC, Weschler B, Frances C, Papo T, Godeau P. Exclusion criteria for primary antiphospholipid syndrome. J Rheumatol 1993; 20: 1802–1804.PubMedGoogle Scholar
  58. 58.
    Krnic-Barrie S, O’Connor CR, Looney S, Pierangeli S, Harris N, Phil M. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997; 157: 2101–2108.PubMedCrossRefGoogle Scholar
  59. 59.
    Granados J, Vargas-Alarcon G, Drenkard C et al. Relationship of anticardiolipin antibodies and antiphopholipid syndrome to HLA-DR7 in Mexican patients with SLE. Lupus 1997; 6: 57–62.PubMedCrossRefGoogle Scholar
  60. 60.
    Silver RM, Draper MJ, Scott JR, Lyon JL, Reading J, Branch DW. Clinical consequences of antiphospholipid antibodies. An historic cohort study. Obstet Gynecol 1994; 83: 372–377.PubMedGoogle Scholar
  61. 61.
    Mujic F, Cuadrado MJ, Lloyd M et al. Primary antiphospholipid syndrome evolving into SLE. J Rheumatol 1995; 22: 1589–1592.PubMedGoogle Scholar
  62. 62.
    Seisdedos L, Munoz-Rodriguez F J, Cervera R, Font J, Ingelmo M. Primary antiphospholipid syndrome evolving into SLE. Lupus 1997; 6: 285–286.PubMedCrossRefGoogle Scholar
  63. 63.
    Galli M, Finazzi G, Barbui T. Thrombocytopenia in the antiphospholipid syndrome: pathophysiology, clinical relevance and treatment. Ann Med Interne 1996; 147 (Suppl 1): 24–27.Google Scholar
  64. 64.
    Hojnik M,George J, Ziporen L, Schonfeld Y. Heart valve involvement in the antiphopsholipid sydrome. Circulation 1996; 93: 1579–1587.PubMedCrossRefGoogle Scholar
  65. 65.
    Coudray N, de Zuttere D, Bletry O et al. M mode and Doppler echocardiographic assessment of left ventricular diastolic function in primary antiphospholipid syndrome. Br Heart J 1995; 74: 531–535.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2000

Authors and Affiliations

  • T. Godfrey
  • D. D’Cruz

There are no affiliations available

Personalised recommendations